Previews

Biotech stocks advanced in the holiday-shortened week, with upside driven mainly by the broader market strength. Reflecting the extreme volatility in the space, a few stocks gyrated wildly in reaction to catalytic events. ChemoCentryx Inc (NASDAQ: CCXI) nearly tripled in a single session in...

Biotech stocks had a fairly robust November, with the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) advancing over 10% for the month. This compares to the 3% gains for the S&P 500 Index. The month witnessed eight new molecular entity, or NME, approvals, taking the total NME approvals for the...

Biotech stocks experienced some momentum last week amid a few clinical readouts. Karuna Therapeutics Inc (NASDAQ: KRTX), which went public in June, was among the biggest gainers of the week on a positive mid-stage readout for its schizophrenia drug. Bristol-Myers Squibb Co (NYSE: BMY)...

Tesla Inc (NASDAQ: TSLA) is gearing up to unveil what CEO Elon Musk calls its “best product ever” Thursday night in Los Angeles. The electric pickup truck, or cybertruck, as Musk calls it, is claiming related IP rights. Tesla has filed to trademark a “CYBRTRK” logo and has...

Biotech stocks went about a consolidation move last week, although a few swung wildly in either direction in reaction to some catalytic events. Aslan (NASDAQ: ASLN) tumbled after its late-stage biliary tract cancer drug candidate flunked a pivotal study. Lipocine Inc's (...

For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud. The IPO dates below are expected but not confirmed. Sitime Corp (NASDAQ: SITM) will issue 4.3 million shares between $13 and $15 Thursday on the Nasdaq. The offering represents about 30% of outstanding shares and is...

Medical supplier Becton Dickinson and Co (NYSE: BDX) is scheduled to release fiscal fourth-quarter results Tuesday ahead of the market open. The Thesis Becton is likely to wrap the year on a strong note on both the top- and bottom-line, according to JPMorgan Securities analysts. The research...

Biotech stocks extended their gains last week amid earnings news flow and the broader market strength. Large-cap pharma stocks saw particular strength. Here are the key catalytic event a biotech investor should keep a tab on in the unfolding week. Conferences American Society of Nephrology Kidney...

For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud. The IPO dates below are expected but not confirmed. Osprey Technology Acquisition Corp. (NYSE: SFTWU) will issue 25 million shares at $10 Friday, Nov. 1, on the New York Stock Exchange. The offering represents about 11...

The FDA worked overtime in October, deciding on the fate of several therapies and treatment options. Most reviews produced positive outcomes. Three new molecular entities, or NMEs, were approved in October, taking the total number of NME approvals for the year to 33 compared to 47 approvals by the...

Facebook, Inc. (NASDAQ: FB) is reporting its third-quarter earnings after Wednesday's close. Benzinga took a look back at Facebook’s other seven third-quarter earnings reports to look for any potential patterns in how the stock reacts. Q3 2018: shares up 3.8% the first day following the...

Apple, Inc (NASDAQ: AAPL) will report its fiscal fourth-quarter earnings after Wednesday's close. Benzinga took a look back at Apple’s last seven fourth-quarter earnings reports to look for any potential patterns in how the stock reacts. Q4 2018: shares down 6.6% the day following the...

Apple Inc. (NASDAQ: AAPL) shares have been flirting with record highs in recent sessions, thanks to upbeat expectations surrounding the uptake of the latest iPhone. The Cupertino, California-based company is set to report fourth-quarter results Wednesday after the market close. Upbeat Q4...

For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud. The IPO dates below are expected but not confirmed. Leaping Group Co., Ltd. (NASDAQ: YZCM) will issue 4 million shares at $5 Thursday on the Nasdaq. The offering represents about 20% of outstanding shares and is...

Earnings, clinical trial readouts and positive FDA verdicts catalyzed fairly robust performances by biotech stocks last week. Biogen Inc (NASDAQ: BIIB)'s about-face with respect to its Alzheimer's drug aducanumab headlined the biotech news, while Seattle Genetics (NASDAQ: SGEN)...